NEW YORK, Feb. 28, 2018
/PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage
biopharmaceutical company developing novel therapies for
neurodegenerative diseases, including Alzheimer's disease (AD),
today announced that Daniel Alkon,
MD, President and Chief Scientific Officer of Neurotrope, will
present at the Cowen and Company 38th Annual Health Care
Conference to be held at the Boston Marriott Copley Place,
from March 12th - 14th, 2018. The
Corporate presentation is scheduled for Monday, March 12th at 4:50 PM.
A live audio webcast of the presentation will be accessible
through Neurotrope's Investor Relations website at
http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/Investors.html
An archived edition of the session will be available later that
day.
About Neurotrope
Neurotrope is at the forefront of developing a new approach to
combating AD and other neurodegenerative diseases. The
Company's world-class science offers the potential to realize a
paradigm shift to overcome one of today's most challenging clinical
problems — finding a way to slow or even prevent the progression of
AD.
In addition to the Company's Phase 2 trial of bryostatin-1 in
advanced AD, Neurotrope has also conducted preclinical studies of
bryostatin as a potential treatment for Fragile X Syndrome, Stroke,
Traumatic Brain Injury, and Niemann-Pick Type C disease and Rett
Syndrome—rare genetic diseases for which only symptomatic
treatments are currently available. The FDA has granted Orphan Drug
Designation to Neurotrope for Bryostatin-1 as a treatment for
Fragile X Syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs in
AD.
Please visit www.neurotropebioscience.com for further
information.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for Alzheimer's dementia and
other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. These statements are subject
to the risk that further analyses of the Phase 2 data may lead to
different interpretations of the data than the analyses conducted
to date and/or may identify important implications of the Phase 2
data that are not reflected in these statements. Clinical trial
data are subject to differing interpretations, and regulatory
agencies, medical and scientific experts and others may not share
the Company's views of the Phase 2 data. There can be no assurance
that the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand the Company's business,
significant government regulation of pharmaceuticals and the
healthcare industry, lack of product diversification, availability
of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the
Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including the
Company's Annual Report on Form 10-K for the year
ended December 31, 2016 and on Form 10-Q for the quarter
ending September 30, 2017. The Company does not undertake to
update these forward-looking statements.
Contact information:
Investors and Media
Jeffrey Benison, Director of Corporate Communications
Neurotrope Bioscience, Inc.
516.286.6099
jbenison@neurotropebioscience.com
View original
content:http://www.prnewswire.com/news-releases/neurotrope-to-present-at-the-cowen-and-company-38th-annual-health-care-conference-300604866.html
SOURCE Neurotrope, Inc.